KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.65

A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).

Keita Sasaki, Motoo Nomura, Ken Kato, Katsuyuki Sakanaka, Yoshinori Ito, Tomohiro Kadota, Ryunosuke Machida, Tomoko Kataoka, Keiko Minashi, Yasuhiro Tsubosa, Takeshi Kajiwara, Haruhiko Fukuda, Hiroya Takeuchi, Takashi Mizowaki, Yasumasa Nishimura, Yuko Kitagawa

Jpn J Clin Oncol 54(1) 103-107

PMID37801434
PMCID-
DOI10.1093/jjco/hyad137
发表日期2023-10-06
入排依据:This is a protocol for an ongoing Phase III randomized trial in oncology with a primary time-to-event endpoint, but it does not present results. The eligibility criteria require original formal-result reports of completed trials. Additionally, the drug intervention (specific chemotherapy agent(s)) is not explicitly detailed in the provided record, which is needed to confirm a drug-containing intervention.
摘要

摘要

Chemoradiotherapy has been considered as one of the standard treatment options for clinical T1bN0M0 esophageal squamous cell carcinoma with organ preservation. However, 20% of patients develop locoregional recurrence after chemoradiotherapy, which requires salvage treatment including salvage surgery and endoscopic resection. Salvage surgery can cause complications and treatment-related death. Interestingly, chemoradiotherapy with elective nodal irradiation has been reported to reduce the locoregional recurrence of advanced esophageal squamous cell carcinoma. Hence, we are conducting a clinical trial to confirm whether modified chemoradiotherapy with elective nodal irradiation was superiority to that without elective nodal irradiation for the patients with cT1bN0M0 esophageal squamous cell carcinoma. The primary endpoint is major progression-free survival, defined as the time from randomization to the date of death or disease progression, excluding successful curative resection through salvage endoscopic resection. We plan to enroll 280 patients from 54 institutions over 4 years. This trial has been registered in the Japan Registry of Clinical Trials (jRCTs031200067).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。